Colloid formation by drugs in simulated intestinal fluid

Journal of Medicinal Chemistry

Volumn 53, Issue 10, 2010, Pages 4259-4265

  Doak, Allison K ^a   Wille, Holger ^a   Prusiner, Stanley B ^a   Shoichet, Brian K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL NICOTINATE; AMIODARONE; BUFFER; CANDESARTAN HEXETIL; CELECOXIB; CHLORPROMAZINE; CINNARIZINE; CLOFAZIMINE; CLOPIDOGREL; DELAVIRDINE; ETRAVIRINE; FENOFIBRATE; GEFITINIB; IMATINIB; ITRACONAZOLE; MANIDIPINE; MECLOZINE; MENATETRENONE; METHYLENE BLUE; NELFINAVIR; PRANLUKAST; RALOXIFENE; TRICLABENDAZOLE;

ARTICLE; COLLOID; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; IN VIVO STUDY; INTESTINE FLUID; SIMULATION; SMALL INTESTINE;

BUFFERS; CHEMICAL PRECIPITATION; COLLOIDS; INTESTINE, SMALL; LIGHT; MICROSCOPY, ELECTRON, TRANSMISSION; PHARMACEUTICAL PREPARATIONS; SCATTERING, RADIATION; SOLUBILITY;

EID: 77952733763     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100254w     Document Type: Article

References (38)

1. Keseru, G. M.; Makara, G. M. Hit discovery and hit-to-lead approaches Drug Discovery Today 2006, 11, 741-748
2. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition J. Med. Chem. 2003, 46, 4265-4272
3. Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening Drug Discovery Today 2003, 8, 86-96
4. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von der Saal, W.; Zimmermann, G.; Schneider, G. Development of a virtual screening method for identification of frequent hitters in compound libraries J. Med. Chem. 2002, 45, 137-142 (Pubitemid 34038548)
5. Crisman, T. J.; Parker, C. N.; Jenkins, J. L.; Scheiber, J.; Thoma, M.; Kang, Z. B.; Kim, R.; Bender, A.; Nettles, J. H.; Davies, J. W.; Glick, M. Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data J. Chem. Inf. Model. 2007, 47, 1319-1327
6. DeWitte, R. S. Avoiding physicochemical artefacts in early ADME-Tox experiments Drug Discovery Today 2006, 11, 855-859
7. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-throughput assays for promiscuous inhibitors Nat. Chem. Biol. 2005, 1, 146-148
8. Liu, H. Y.; Wang, Z.; Regni, C.; Zou, X.; Tipton, P. A. Detailed kinetic studies of an aggregating inhibitor; inhibition of phosphomannomutase/ phosphoglucomutase by disperse blue 56 Biochemistry 2004, 43, 8662-8669
9. Reddie, K. G.; Roberts, D. R.; Dore, T. M. Inhibition of kinesin motor proteins by adociasulfate-2 J. Med. Chem. 2006, 49, 4857-4860
10. Coan, K. E.; Maltby, D. A.; Burlingame, A. L.; Shoichet, B. K. Promiscuous aggregate-based inhibitors promote enzyme unfolding J. Med. Chem. 2009, 52, 2067-2075
11. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 2000, 351, 95-105
12. Lingameneni, R.; Vysotskaya, T. N.; Duch, D. S.; Hemmings, H. C., Jr. Inhibition of voltage-dependent sodium channels by Ro 31-8220, a specific protein kinase C inhibitor FEBS Lett. 2000, 473, 265-268
13. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: not just for kinases anymore J. Med. Chem. 2003, 46, 1478-1483
14. Coan, K. E.; Shoichet, B. K. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors J. Am. Chem. Soc. 2008, 130, 9606-9612
15. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs J. Med. Chem. 2003, 46, 4477-4486
16. Frenkel, Y. V.; Clark, A. D., Jr.; Das, K.; Wang, Y. H.; Lewi, P. J.; Janssen, P. A.; Arnold, E. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability J. Med. Chem. 2005, 48, 1974-1983
17. Janssen, P. A.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A. D., Jr.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1 E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J. Med. Chem. 2005, 48, 1901-1909
18. Lewi, P.; Arnold, E.; Andries, K.; Bohets, H.; Borghys, H.; Clark, A.; Daeyaert, F.; Das, K.; de Bethune, M. P.; de Jonge, M.; Heeres, J.; Koymans, L.; Leempoels, J.; Peeters, J.; Timmerman, P.; Van den Broeck, W.; Vanhoutte, F.; Vant Klooster, G.; Vinkers, M.; Volovik, Y.; Janssen, P. A. Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds Drugs R&D 2004, 5, 245-257
19. Coan, K. E.; Shoichet, B. K. Stability and equilibria of promiscuous aggregates in high protein milieus Mol. BioSyst. 2007, 3, 208-213
20. Flynn, B. C.; Sladen, R. N. The use of methylene blue for vasodilatory shock in a pediatric lung transplant patient J. Cardiothorac. Vasc. Anesth. 2009, 23, 529-530
21. Oz, M.; Lorke, D. E.; Petroianu, G. A. Methylene blue and Alzheimers disease Biochem. Pharmacol. 2009, 78, 927-932
22. Wainwright, M. The use of dyes in modern biomedicine Biotech. Histochem. 2003, 78, 147-155
23. Ryan, A. J.; Gray, N. M.; Lowe, P. N.; Chung, C. W. Effect of detergent on promiscuous inhibitors J. Med. Chem. 2003, 46, 3448-3451
24. Jadhav, A.; Ferreira, R. S.; Klumpp, C.; Mott, B. T.; Austin, C. P.; Inglese, J.; Thomas, C. J.; Maloney, D. J.; Shoichet, B. K.; Simeonov, A. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease J. Med. Chem. 2009, 53, 37-51
25. Feng, B. Y.; Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors Nat. Protoc. 2006, 1, 550-553
26. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv. Drug Delivery Rev. 2008, 60, 717-733
27. Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 2000, 11 (Suppl. 2) S73-S80
28. Jantratid, E.; Janssen, N.; Reppas, C.; Dressman, J. B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 2008, 25, 1663-1676
29. Sutton, S. C. Role of physiological intestinal water in oral absorption AAPS J. 2009, 11, 277-285
30. Marciani, L.; Foley, S.; Hoad, C.; Campbell, E.; Totman, J.; Armstrong, A.; Manby, P.; Gowland, P. A.; Spiller, R. Effects of Ondansetron on Small Bowel Water Content: A Magnetic Resonance Imaging Study. Presented at the 15th United European Gastroenterology Week, Paris, October 27-31, 2007.
31. Marciani, L.; Foley, S.; Hoad, C.; Campbell, E.; Totman, J.; Cox, E.; Gowland, P.; Spiller, R. C. Magnetic Resonance Imaging of Abnormalities in Diarrhoea-Predominant Irritable Bowel Syndrome Fasting and after a Bran-Containing Meal. Presented at the 15th United European Gastroenterology Week, Paris, October 27-31, 2007.
32. Schiller, C.; Frohlich, C. P.; Giessmann, T.; Siegmund, W.; Monnikes, H.; Hosten, N.; Weitschies, W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 2005, 22, 971-979
33. Galia, E.; Nicolaides, E.; Horter, D.; Lobenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 1998, 15, 698-705
34. Kostewicz, E. S.; Brauns, U.; Becker, R.; Dressman, J. B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media Pharm. Res. 2002, 19, 345-349
35. Nicolaides, E.; Galia, E.; Efthymiopoulos, C.; Dressman, J. B.; Reppas, C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data Pharm. Res. 1999, 16, 1876-1882
36. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26 (Pubitemid 33653411)
37. Mott, B. T.; Ferreira, R. S.; Simeonov, A.; Jadhav, A.; Ang, K. K.; Leister, W.; Shen, M.; Silveira, J. T.; Doyle, P. S.; Arkin, M. R.; McKerrow, J. H.; Inglese, J.; Austin, C. P.; Thomas, C. J.; Shoichet, B. K.; Maloney, D. J. Identification and optimization of inhibitors of trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB J. Med. Chem. 2009, 53, 52-60
38. Wille, H.; Govaerts, C.; Borovinskiy, A.; Latawiec, D.; Downing, K. H.; Cohen, F. E.; Prusiner, S. B. Electron crystallography of the scrapie prion protein complexed with heavy metals Arch. Biochem. Biophys. 2007, 467, 239-248